Colchicine for the Stability of Coronary Plaque in Acute Coronary Syndrome (COLOCT)

PHASE4CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

August 20, 2023

Study Completion Date

October 5, 2023

Conditions
Acute Coronary Syndrome
Interventions
DRUG

Colchicine

colchicine is a potent anti-inflammatory drug which is currently recommended for the treatment of pericarditis and acute gout attacks, but also familial Mediterranean fever and Behçet disease. This drug acts on inflammation through inhibition of microtubule polymerization by binding free tubule dimers. Colchicine blunts monocyte and neutrophil invasion at the site of inflammation and reduces intracellular trafficking and thus the release of cytokine and production of reactive oxygen species and a variety of proteolytic enzymes.

DRUG

Placebo

the placebo is a drug with no chemical effects but with the same physical characteristics as the experiment drug colchine.

Trial Locations (1)

Unknown

Wuhan Union Hospital, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER